Matinas BioPharma Holdings, Inc. Cash Flow Statement
MTNB|10 years of annual SEC 10-K data (FY2015-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Matinas BioPharma Holdings, Inc. used $16M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$24.3M | -$21.0M | -$23.3M | -$23.3M | -$22.4M | -$14.1M | -$15.5M | -$9.1M | -$7.6M | -$9.1M |
| Depreciation & Amortization | $365.0K | $337.0K | $244.0K | $244.0K | $231.1K | $218.3K | $100.6K | $43.5K | $52.6K | $43.5K |
| Operating Cash Flow | -$15.9M | -$19.2M | -$15.2M | -$15.2M | -$17.4M | -$10.3M | -$11.5M | -$7.8M | -$6.1M | -$7.8M |
| Capital Expenditures | - | $892.0K | $260.0K | $260.0K | $5.7K | $535.9K | $942.2K | $76.2K | $0 | $76.2K |
| Free Cash Flow | - | -$20.0M | -$15.5M | -$15.5M | -$17.4M | -$10.9M | -$12.4M | -$7.9M | -$6.1M | -$7.9M |
| FCF Margin | - | -628.9% | -46918.2% | -46918.2% | -10972.8% | -9066.5% | -8285.1% | -4057.0% | - | -4057.0% |